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INTRODUCTION
We recently observed that, paradoxically, a single injec-
tion of recombinant interleukin (IL)-12 on the day of bone
m a rrow transplantation (BMT) inhibits acute graft-vs.-host
disease (GVHD) in a fully mismatched (MHC plus multiple
minor antigens) murine BMT model [1]. The pro t e c t i v e
e ffect of IL-12 against GVHD was surprising. This cytokine
is known to induce Th1 diff e rentiation and enhance cyto-
toxic T-lymphocyte (CTL) function, and both Th1 immune
responses and CTLs have been implicated in the pathogene-
sis of acute GVHD [2–15], including the fully mismatched
model in which the protective effect of IL-12 was originally
d i s c o v e red [1]. Surprisingly, the ability of IL-12 to inhibit
GVHD is dependent on the cytokine interf e ron (IFN)-g
[16,17], which is generally associated with Th1 re s p o n s e s .
Initial studies addressing the mechanism of this eff e c t
showed that early expansion of donor T cells, which occurs
in the first week post-BMT [14], was inhibited by IL-12 in
an IFN-g–dependent manner [1,17]. Furt h e rm o re, GVL
e ffects against a host-type T-cell leukemia/lymphoma were
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ABSTRACT
P a r a d o x i c a l l y, a single injection of recombinant murine interleukin (IL)-12 on the day of bone marrow transplanta-
tion (BMT) inhibits graft-vs.-host disease (GVHD) while pre s e rving graft-vs.-leukemia (GVL) effects in lethally
i rradiated mice receiving fully MHC-mismatched bone marrow and spleen cells. These protective effects are medi-
ated by interf e ron (IFN)-g, whose early secretion is induced by IL-12 treatment. We investigated the relationship of
IL-12 dose and timing of administration, as well as timing and type of total-body irradiation (TBI), with the ability
of IL-12 to inhibit GVHD or mediate toxicity. The results show that a relatively low dose of IL-12 (as little as 50 U
in a single injection) can mediate significant GVHD protection. The timing of IL-12 administration, however, is a
critical factor. IL-12 administered 1 hour before BMT was most protective, but protection was still observed when
it was administered 1–12 hours after BMT. Delaying IL-12 administration to 36 hours post-BMT completely obvi-
ated its protective effect. Administration of a second IL-12 injection 6 days after BMT negated the protective eff e c t
of an initial injection at the time of BMT. While IL-12 protection was evident when TBI was administered by 1 3 7C s -
i rradiator in one or two fractions on day –1 or day 0, the use of an X-irradiator to deliver TBI on day –1 was associ-
ated with marked IL-12 toxicity. Whereas the protective effect of IL-12 against GVHD depended on donor- d e r i v e d
I F N -g, toxicity depended on the ability of host cells to produce IFN-g. Careful studies are warranted to test the
e ffects of IL-12 in the context of BMT with various conditioning regimens in large animal preclinical models before
this novel approach to GVHD protection can be applied clinically.
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p re s e rved in IL-12–treated mice, and these GVL effects were
at least partly dependent on IFN-g [18]. However, adminis-
tration of exogenous IL-12 has been associated with signifi-
cant toxicity under some circumstances in murine [1,19,20]
and human [19,21] studies, and this toxicity has been associ-
ated with high levels of IFN-g [1,19]. Thus, a critical issue in
the application of this novel approach to inhibiting GVHD
while pre s e rving the beneficial GVL effects of allogeneic
BMT is whether IL-12 in GVHD-protective dose re g i m e n s
might lead to significant toxicity in association with clinically
relevant conditioning regimens. In this study, there f o re, we
have explored the relationship between IL-12 dose and tim-
ing, mode and timing of TBI administration, and IL-
12–induced GVHD protection and toxicity.
MATERIALS AND METHODS
M i c e
B10.BR/SgSnJ (H2k)784 and C57BL/6-IFN knockout
mice were purchased from the Jackson Laboratory (Bar Har-
b o r, ME). C57BL/6 (H2b) and A/J (H2a) mice were purc h a s e d
f rom the Frederick Cancer Research Facility of the National
Institutes of Health (Frederick, MD). Mice were housed in a
s p e c i fic pathogen–free facility in microisolator cages. Donors
and recipients were used at 8–16 weeks of age, and re c i p i e n t s
within an individual experiment were age-matched. 
GVHD induction
Recipients were irradiated in a single fraction (unless
o t h e rwise indicated) with 9 .0 Gy TBI by X-ray 
(39 cGy/min) on day –1 or with 9.75 Gy TBI by 1 3 7C s
s o u rce (85–90 cGy/min) on day –1 or day 0, as indicated.
Recipients were given an intravenous infusion of 8–103106
donor bone marrow (BM) that was T-cell–depleted (TCD)
by treatment with anti-Thy1.2 (clone 30-H-12, provided by
D r. David H. Sachs, Boston, MA) and complement as
described [22] or with 6–103106 untreated donor BM cells.
Donor BM was supplemented with 0, 531 06, or 1531 06
donor splenocytes, as indicated, in the B6 to B10.BR strain
combination or with 11–1531 06 donor splenocytes in the
A/J to B6 strain combination. In the latter combination,
4–53106 TCD B6 BMC (depleted of T cells with anti-CD4
plus CD8 monoclonal antibodies plus complement as previ-
ously described [23]) were coadministered in the inoculum,
which has been shown to provide an additive pro t e c t i v e
e ffect and hence to augment the ability to detect GVHD-
i n h i b i t o ry effects of IL-12 [1]. Syngeneic controls in this
strain combination received 4–53106 TCD B6 marrow cells
alone. Mice were weighed and observed for evidence of
GVHD once or twice weekly and observed daily for surv i v a l .
IL-12 administration
Recombinant murine IL-12 (provided by Genetics Insti-
tute, Cambridge, MA), specific activity 3.3–5.531 06 U / m g ,
was injected intraperitoneally into recipient mice at the times
indicated. Dosing and duration of treatment are indicated
b e l o w. 
Statistical anal y s e s
G roup comparisons of continuous data were made by Stu-
d e n t ’s t test. Survival data were analyzed by lifetable methods,
and significance was determined using the Mantel-Peto-Cox
s u m m a ry of x2 [24] or the log-rank test. Actuarial survival rates
are shown. p values ,0.05 were considered to be significant. 
RESULTS
Dose r e q u i r ement for IL-12–induced GVHD
p ro t e c t i o n
Using the A/J→B6 strain combination, we pre v i o u s l y
demonstrated that a single injection of 4900–5000 U recom-
binant murine IL-12 given ~4–6 hours after lethal TBI by
137Cs and 1 hour before BMT on day 0 led to GVHD pro-
tection that was equal to or better than that achieved with
repeated IL-12 injections on days 0 and 1 or days 0, 1, and 2
[1]. To determine the minimal amount of IL-12 given on
day 0 that could provide GVHD protection, we initially
c o m p a red the protection aff o rded by one-half and one-
q u a rter of this “standard” dose. A similar delay in GVHD
m o rtality occurred when IL-12 was given at any of these
doses (median survival time [MST] 8 days for GVHD con-
trols, 24.5 days with 4900 U IL-12, 21.5 days with 2450 U,
and 21.5 days with 1225 U; p , 0.005 for all three IL-
1 2 – t reated groups compared with controls; no significant
difference comparing the three groups receiving IL-12 with
one another). Next, we compared the protective effect of
f u rther decreasing doses of IL-12. As is shown in Figure 1A,
as little as 200 U of IL-12, given ~1 hour before BMT, led
to statistically significant GVHD protection. Surprisingly,
the delay in GVHD mortality induced by this IL-12 dose
was similar to that achieved with three- and 12-fold greater
IL-12 doses in the same experiments. 
In a further eff o rt to determine the minimal IL-12 dose
re q u i red for GVHD protection, we compared doses of 50,
200, or 2400 U IL-12. As shown in F i g u re 1B, a statistically
s i g n i ficant protective effect (p , 0.05) was measurable with the
lowest IL-12 dose administered. The degree of protection was
not greatly enhanced by a fourfold increase in IL-12 dose to
200 U (both groups showed an MST of 18 days, compare d
with 7 days for GVHD control mice), but the delay in GVHD
m o rtality was further increased in the group that re c e i v e d
2400 U IL-12, which delayed the MST to 30 days (p , 0 . 0 0 1
c o m p a red with controls). However, the diff e rences in surv i v a l
between recipients of the three diff e rent IL-12 doses did not
achieve statistical significance, perhaps because of the re l a-
tively small number of animals in each group. Nevert h e l e s s ,
our results suggest that the level of protection aff o rded by IL-
12 became submaximal in the 50–200 U dose range.
A dose titration was also performed in the B6→B10.BR
strain combination, in which TBI was given by 1 3 7Cs in a
single fraction on day 0, the day of BMT. As shown in
F i gu re 2, either 3300 or 330 U IL-12 was capable of pro-
tecting in this model, but only the higher IL-12 dose led to
a statistically significant degree of GVHD protection (p ,
0.05 for 3300 U and p 5 0.06 for 330 U compared with con-
trols). Thus, while a mild protective effect was apparent at
the lower IL-12 dose, a dose effect could be discerned in the
330–3300 U IL-12 dose range in this strain combination.
Optimal timing of IL-12 administration
As discussed above, we previously demonstrated that a
single IL-12 injection on day 0 mediated protective effects
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similar to those achieved with repeated injections on days 0,
1, and 2. Our usual time of IL-12 administration on day 0 is
a p p roximately 4–6 hours after TBI by 1 3 7Cs and 1 hour
b e f o re BMT. To determine the optimal timing of IL-12
administration, we compared the effect of giving IL-12 1
hour before BMT, 1 hour after BMT, and 12, 36, or 72
hours after BMT in the A/J→B6 strain combination. We
also pre p a red similarly irradiated syngeneic BMT contro l
groups receiving similar IL-12 inocula to assess the poten-
tial toxicity of IL-12 administration at each time point. As
shown in Fig. 3A, slightly greater GVHD protection was
o b s e rved in mice receiving IL-12 1 hour pre-BMT (p , 0 . 0 5
c o m p a red with controls) than in those receiving IL-12 1
hour post-BMT (p 5 0.07 compared with controls). How-
ever, the difference between these two IL-12–treated groups
did not achieve statistical significance. Although some
degree of protection was achieved with IL-12 administrat i o n
12 hours after BMT (MST 19 days compared with 7 days for
GVHD controls), the degree of this protection was less than
that achieved with IL-12 administration 1 hour pre- or post-
BMT (MST 30 and 24.5 days, respectively), and surv i v a l
p rolongation did not achieve statistical significance com-
p a red with controls. Administration of IL-12 36 hours after
B M T, in contrast, had a deleterious effect, leading to
m o rtality that was significantly more rapid than that in the
c o nt rol group receiving no IL-12 (p , 0.05). IL-12 adminis-
t r ation 72 hours post-BMT was not associated with any
acceleration of or delay in mortality compared with con-
trols. The accelerated mortality in the group receiving allo-
geneic BMT/spleen cells and IL-12 treatment 36 hours
post-BMT may have reflected a toxic effect of IL-12, as one
mouse in the syngeneic control group receiving IL-12 at
36 hours also died on day 7 (Fig. 3B). In contrast, syngeneic
control mice receiving IL-12 1 hour pre- or post-BMT or
12 or 72 hours post-BMT showed no mortality or other evi-
dence of toxicity. Thus, to provide a protective effect against
GVHD, it was necessary to administer IL-12 close to the
time of BMT. Although a delay of 12 hours in its adminis-
tration was associated with some protection, maximal pro-
tection was observed when IL-12 was administered 1 hour
b e f o re allogeneic BMT. Furt h e rm o re, IL-12 appeared to
have a toxic effect when administered 36 hours after BMT.
Since pretransplant IL-12 administration seemed to
provide superior protection to IL-12 given as early as 1 hour
p o s t - B M T, we also examined the effect of administering IL-12
a full day before BMT. As shown in Fig. 4, in the A/J→B6
strain combination, animals that were conditioned with TBI
by 1 3 7Cs and received allogeneic BMT without IL-12
Figure 1. IL-12–induced GVHD protection
A: Dose titration. B6 mice received 9.75 Gy TBI from a 137Cs-irradiator on
day 0, followed by BMT with 6–831 06 TCD A/J BMC and 11–1331 06
A/J spleen cells, along with 53106 TCD B6 BMC. They received no IL-12
(j) or an intraperitoneal injection of 200 (n), 600 (.), or 2400 (h) U IL-
12 ~1 hour before BMT. n514–16 per group. Syngeneic BMT recipients of
no IL-12 (n52) or 2400 U IL-12 (n56) showed 100% survival for the
entire follow-up period (not shown). Results of two similar experiments are
combined. B. As little as 50 U IL-12 administered intraperitoneally ~1 hour
before BMT causes a significant delay in GVHD mortality. B6 mice received
9.75 Gy TBI from a 137Cs irradiator on day 0, followed by BMT with 93106
TCD A/J BMC and 133106 A/J spleen cells, along with 53106 TCD B6
BMC. They received no IL-12 (j; n55) or an intraperitoneal injection of 50
(m; n57), 200 (n; n57), or 2400 (h; n57) U IL-12. A statistically
significant protective effect (p < 0.05) was measurable with the lowest IL-12
dose administered (50 U). Syngeneic BMT controls (n52; not shown) demon-
strated 100% survival.
Figure 2. Dose titration of IL-12–induced GVHD protection
in the B6 →B10.BR strain combination
B10.BR mice received 9.75 Gy TBI from a 137Cs irradiator on day 0, followed
by transplantation with 83106 TCD B6 BMC with no IL-12 treatment (j)
or 330 (n) or 3300 (.) U IL-12 on day 0. Additional groups received
153106 B6 spleen cells in addition to the TCD BMC, and no further treat-
ment (r) or 330 (s) or 3300 (g ) U IL-12 on day 0. n58 per group.
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showed an MST of 7 days. With administration of 2450 U
IL-12 on day 0 (~1 hour before BMT), the MST was pro-
longed to 22 days (p , 0.01). However, administration of a
similar dose of IL-12 on day –1, one day before TBI and
B M T, was associated with a reduction in this pro t e c t i v e
effect, so that the MST was reduced to 8 days. While sur-
vival prolongation in this group, when compared with
GVHD controls, just missed achieving statistical signifi-
cance (p 5 0.05), two animals that received IL-12 on day –1
survived into the 4th week post-BMT, whereas all of those
in the GVHD control group had succumbed by day 8. The
GVHD protection associated with administration of IL-12
on day –1 might have been mitigated by a toxic effect of giv-
ing IL-12 at this time, since two of three syngeneic BMT
recipients of this IL-12 treatment died on days 8 and 22.
Although the number of animals in this syngeneic contro l
group was too small to allow firm conclusions about IL-12
toxicity, syngeneic controls not receiving IL-12 or receiving
IL-12 on day 0 survived beyond 50 days.
We also performed an experiment in the A/J→B6 strain
combination to determine whether a second dose of IL-12
administered 6 days after BMT and an initial (pre-BMT, day
0) IL-12 injection might overcome or augment the protec-
tive effect against GVHD. A repeat injection of IL-12 on
day 6 completely negated the protective effect of IL-12
administered on day 0 (data not shown). GVHD controls in
this experiment had a median survival time of 8 days,
whereas those receiving a single injection of 2400 U IL-12
on day 0 alone had a MST that was prolonged to 28 days. In
contrast, a group receiving 2400 U of IL-12 on both days 0
and 6 had a median survival time of only 9 days (p , 0.005
compared with recipients of 2400 U IL-12 on day 0 only).
All syngeneic controls receiving no IL-12, a single IL-12
injection on day 0, or IL-12 on both days 0 and 6 showed
100% survival, with no evidence of toxicity (data not
shown).
IL-12 protection in mice receiving 1 3 7Cs irradiation in
one or two fractions on day –1
We perf o rmed further studies in the A/J→B6 strain
combination to determine whether the timing and mode of
administration of TBI could affect the protective ability or
toxicity of IL-12 in BMT recipients. We first compared the
ability to achieve IL-12–induced GVHD protection when
TBI was administered in a single fraction on day 0 or day –1
and IL-12 was administered on day 0. Similar GVHD sur-
vival curves were observed in non–IL-12-treated GVHD
controls that received irradiation on either day –1 or day 0
(MST 8 days for both groups; data not shown). IL-12 treat-
ment (2400 U on day 0) led to significant GVHD protection
in mice that received TBI on day –1 (MST 49 days; p ,
0.05). In mice that were irradiated on day 0 in the same
experiment, IL-12 treatment led to survival pro l o n g a t i o n
Figure 3. Timing of IL-12 administration
A. Optimal timing of IL-12 administration for GVHD protection. Lethally
irradiated (9.75 Gy, 137Cs irradiator, day 0) B6 mice received 73106 TCD
A/J BMC and 133106 A/J spleen cells, along with 53106 TCD B6 BMC.
They received no IL-12 ( j ; n57) or an intraperitoneal injection of 4000 U
IL-12 ~1 hour before BMT (r; n57), 1 hour post-BMT (s; n58), 12
hours post-BMT (h; n58), 36 hours post-BMT ( g ; n58), or 72 hours post-
BMT (,; n58). B. Syngeneic BMT control groups receiving IL-12 at vari-
ous times in the same experiment as shown in Fig. 3A. Irradiated B6 mice
received 53106 TCD B6 BMC, with 4000 U IL-12 ~1 hour before BMT
(r; n52), 1 hour post-BMT (s; n53), 12 hours post-BMT (h; n53), 36
hours post-BMT (g ; n53), or 72 hours post-BMT (,; n53). 
Figure 4. T oxic effect of IL-12 administered 1 day before 9.75
Gy TBI by 137 Cs-irradiator and BMT
B6 mice received 73106 A/J BMC and 103106 A/J spleen cells, along with
53106 TCD B6 BMC. Survival curves are shown for mice that received TBI
on day 0, and that received no IL-12 (j; n=6) or an intraperitoneal injection
of 2450 U IL-12 ~1 hour before BMT (on day 0) (m; n=7) or ~24 hours
before BMT (on day –1) (,; n=7). Syngeneic BMT controls received similar
irradiation on day 0, with no IL-12 (s; n=2), IL-12 on day 0 ( g ; n=3), or
IL-12 on day –1 (h; n=3).
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(MST 64 days) that did not quite achieve statistical signifi-
cance (p 5 0.06 compared with non–IL-12-treated re c i p i-
ents of TBI on day 0; data not shown). Thus, IL-12 given
on day 0 mediated similar GVHD protection regardless of
whether TBI was administered on day –1 or day 0.
Since TBI is often given clinically in multiple fractions,
we also evaluated the ability of IL-12 to inhibit GVHD
when TBI was given in two fractions 6 hours apart on day
–1. The time course of GVHD mortality was somewhat
slower (p , 0.05) in mice receiving fractionated TBI on day
–1 (MST 18 days) than in mice receiving TBI in a single
fraction on day 0 (MST 7 days; data not shown) in the same
experiment (p , 0.05). Treatment with 2400 U IL-12 led to
significant prolongation of survival in mice that were irradi-
ated on day 0 (MST 30 days, p , 0.001). In the gro u p s
receiving fractionated TBI on day –1, IL-12 treatment pro-
longed survival (MST 58 days), but this prolongation did
not achieve statistical significance (p 5 0.1), pro b a b l y
because of the low number of animals in each group (data
not shown).
Use of X-irradiation on day –1 is associated with IL-
12–induced to x i c i t y
We also examined the ability of IL-12 to mediate
GVHD protection when TBI (9 Gy) was given on day –1
from an X-irradiator. As is shown in Fig. 5A, rapid mortality
was observed in all recipients of 3300 U IL-12 either 1 hour
before or 1 hour after BMT in B10.BR mice that received 9
Gy X-irradiation on day –1 followed by TCD B6 BM alone
(without spleen cells) on day 0, while non–IL-12-tre a t e d
controls showed 100% survival. All mice except one animal
in the IL-12–treated group died by day 3 post-BMT (p ,
0.005 compared with controls). This IL-12 toxicity was
dependent on the type of irradiation administered, since
mice receiving similar IL-12 treatment after conditioning
with 9.75 Gy TBI by 137Cs-irradiator on day 0 in the same
experiment showed no mortality (Fig. 5A), and their weight
c u rves followed a pattern similar to those of non–IL-12-
t reated controls (data not shown). In a repeat experiment,
c o n t rol mice that received TCD BM alone after TBI by X-ray
on day –1 showed 100% survival, whereas administration of
IL-12 at a dose of 330, 990, or 3300 U on day 0 was associ-
ated with significant toxicity, causing mortality in at least
50% of mice (p , 0.01 in all groups compared with con-
trols; data not shown). IL-12 administration (990 U) led to
accelerated mortality in recipients of allogeneic spleen cells
along with TCD BMC, with IL-12–treated mice showing
100% mortality on day 4, whereas GVHD controls had an
MST of 8 days (p , 0.05) (Fig. 5B).
Recipient IFN- g is r e q u i r ed for the toxic effect of IL-
12 in mice given X-irradiation on day –1
We recently demonstrated that the protective effect of
IL-12 against GVHD is mediated by donor IFN-g produc-
tion [17,18] and that GVL effects in IL-12–treated re c i p i-
ents of allogeneic BMT are also somewhat dependent on
IFN-g [18]. Because of the rapid mortality induced by IL-12
in mice given TBI by X-ray on day –1, we considered the
possibility that IL-12 treatment induces recipient cells to
p roduce pro i n f l a m m a t o ry cytokines, which could be toxic.
Because of the ability of IL-12 to induce IFN-g release, we
performed studies in IFN-g–deficient B6 recipients of TCD
B10.BR BMC. As shown in Fig. 6, administration of 3300 U
IL-12 on day 0 led to toxicity and death in 9 Gy X-irradi-
ated B6 recipients of TCD B10.BR marrow (p , 0.00001),
similar to that observed in the reciprocal strain combination
(Fig. 5). When IFN-g–deficient B6 mice were used as recip-
ients, however, there was no difference in survival (Fig. 6) or
weight curves (data not shown) of mice that were or were
not treated with IL-12. Thus, the toxic effect of IL-12 in
X -irradiated mice is dependent on the capacity of the recipi-
ent to produce IFN-g.
DISCUSSION
The results presented here demonstrate that a relatively
low dose of IL-12, given shortly before BMT, can mediate
Figure 5. IL-12 toxicity
A. IL-12–induced toxicity in B10.BR mice receiving 9 Gy TBI by X-irradia-
tor on day –1, but not in mice receiving 9.75 Gy TBI by 137Cs-irradiator on
day 0. Recipients of 9.75 Gy TBI by 137Cs-irradiator on day 0, followed by
administration of 83106 TCD B6 BMC on day 0, with no IL-12 (j ) or
3300 U (n) IL-12 1 hour before BMT are shown. Additional groups received
9 Gy TBI by X-irradiator on day –1, followed by administration of 83106
TCD B6 BMC on day 0, with no IL-12 ( g ) or 3300 U IL-12 1 hour before
(e) or after (d) BMT. n58 per group. B. Acceleration of mortality by IL-
12 in mice receiving 9 Gy TBI by X-irradiator on day –1, followed 43106
TCD B6 BMC and 253106 B6 spleen cells (depleted of NK cells with anti-
NK1.1 monoclonal antibody and complement) with no IL-12 (j ) or 990 U
IL-12 (, ) on day 0. n57–8 per group. 
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significant inhibitory effects on murine GVHD in fully
MHC-mismatched strain combinations. Nevertheless, a
dose titration is evident, and the absolute dose requirement
for optimal GVHD protection may be somewhat dependent
on strain combination. Thus, the amount of pro t e c t i o n
afforded by 330 U IL-12 in the B6→B10.BR strain combi-
nation was somewhat less than that achieved with 3300 U
IL-12 in the same combination. Studies in the A/J→B 6
strain combination showed no diff e rence in the degree of
protection achieved with ~5000 vs. 2500 U IL-12, and fur-
thermore, a dose effect was not always apparent within the
200–2400 U IL-12 dose range. Indeed, a delay in GVHD
m o rtality was evident when as little as 50 U IL-12 was
given. However, this delay was less marked than that
achieved with higher IL-12 doses in the same experiment,
suggesting that GVHD protection is also dependent on IL-
12 dose in this strain combination. 
Other diff e rences in the experimental design, besides
the differing strain combinations, may explain the vary i n g
IL-12 dose-response relationships in the two strain combi-
nations studied here. These diff e rences include the coad-
ministration of TCD host-type marrow in the A/J→B6 but
not the B6→B10.BR strain combination. Previous studies
have shown that even though TCD host-type marrow is
rapidly destroyed by donor T cells so that full donor
chimerism is achieved, the TCD host-type marrow has an
additive protective effect against GVHD, and hence makes
it easier to detect the delay in GVHD mortality achieved
with IL-12 administration [1]. Although both strain combi-
nations involve full MHC disparities between donor and
host, another diff e rence is that A/J→B6, but not
B6→B10.BR, includes minor histocompatibility antigen dif-
f e rences between donor and host. Diff e rences in GVHD
effector mechanisms are unlikely to explain the differing IL-
12 dose effects, since GVHD in both strain combinations
has been shown to depend largely on CD4-mediated allore-
a c t i v i t y, although CD8 cells also contribute to its severity
[25,26]. 
If specific activities of recombinant human IL-12 are
assumed to be similar to those of the recombinant murine
IL-12 used in our studies, then the lowest dose of IL-12
shown to inhibit GVHD in our studies (50 U > 10 ng >
500 ng/kg) is comparable to the maximal tolerated repeated
dose (500 ng/kg) determined in clinical trials using this
agent in cancer patients [21]. However, specific activities of
recombinant human IL-12 have not been reported in pub-
lished descriptions of this clinical trial [19,21,27], leaving
some uncertainty about this comparison. Furt h e rm o re, the
patients receiving IL-12 in those trials did not receive TBI
at the same time. Thus, determination of the interactions
between TBI and IL-12 in animal models is critical for the
assessment of clinical applicability of this approach to sepa-
rating GVHD and GVL in bone marrow transplant recipi-
ents. The results presented here demonstrate that such con-
ditioning need not induce toxic effects of IL-12, but that the
mode of administration of TBI has a decisive role in deter-
mining whether IL-12 toxicity is increased.
As illustrated in Fig. 5, IL-12 administration was highly
toxic when used in mice that had received X-irradiation on
day –1, but not in mice receiving g-irradiation on day 0 in
the same experiment. g-Irradiation was not associated with
IL-12 toxicity, which was in fact protective against GVHD,
even when the irradiation was delivered on day –1 in one or
two fractions. The studies presented in Fig. 6 illustrate that
the toxic effect of IL-12 in X-irradiated mice also occurs in
the reverse strain combination from that used in Fig. 5 and,
most importantly, that this effect is dependent on the ability
of the host to produce IFN-g. IL-12–induced toxicity has
been associated with high serum levels of IFN-g in both
mice and humans [1,19,27]. Although IFN-g levels have
been shown to correlate with IL-12 toxicity, and it has been
suggested that attenuation of the IL-12–induced IFN-g
response is responsible for the ability of prior administration
of a single IL-12 treatment to inhibit IL-12 toxicity [19],
d i rect evidence for a role of IFN-g in this effect has not
been provided. To our knowledge, the present study is the
first to demonstrate a critical role for IFN-g in this toxicity.
The reason that IL-12 toxicity would be increased in
animals receiving X-irradiation but not g- i rradiation at a
higher dose rate is unclear. It is possible that the amount of
recipient IFN-g released in response to IL-12 is higher in
mice receiving X-irradiation than in those receiving g- i rr a d i-
ation, perhaps because of the increased tissue penetrance of
X-rays [28]; altern a t i v e l y, the sensitivity of the host to IFN-g
release, perhaps due to the release of other toxic cytokines
that can mediate synergistic toxicity with IFN-g, may be
i n c reased in response to X-irradiation compared with g- i rr a-
diation. IL-12 treatment can induce tumor necrosis factor
( T N F ) -a p roduction in mice [20], and g- i rradiation can lead
to the release of cytokines such as IL-1, IL-6, and TNF-a i n
SCID mice [29]. Although we have not detected elevated
T N F -a levels in the sera of IL-12–treated B6 mice re c e i v i n g
g- i rradiation [30], it is possible that this occurs in X-irr a d i-
ated mice as a consequence of greater tissue injury.
F i g u r e 6: Dependence on recipient IFN- g s e c r etion for IL-
12–induced toxicity in mice receiving X-irradiation on day –1
Wild-type (WT) or IFN-g–deficient (GKO) B6 mice received 9 Gy TBI by
X-irradiator on day –1, followed by administration of 83106 TCD B10.BR
on day 0 with or without IL-12 treatment (3300 U on day 0). Survival
curves are shown for B6 WT mice receiving no IL-12 (j), B6 WT mice
receiving IL-12 on day 0 (h), GKO B6 mice receiving no IL-12 (m), and
GKO B6 mice receiving IL-12 on day 0 (n). Results from two similar experi-
ments are combined (total n516 per group). 
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It is of some concern that the same cytokine that is
responsible for the ability of IL-12 to inhibit GVHD, and
that contributes to GVL effects in IL-12–treated mice
[17,18], is also responsible for IL-12–induced toxicity. How-
e v e r, our previous studies using IFN-g knockout donors and
recipients have shown that recipient-derived IFN-g may not
play a critical role in the protective effect of IL-12, where a s
d o n o r-derived IFN-g is essential [17]. In contrast, re c i p i e n t -
derived IFN-g is critical for the toxic effect of IL-12 in
X -i rradiated mice, since X-irradiated IFN-g knockout re c i p-
ients did not show evidence of toxicity when wild-type donor
m a rrow was given (Fig. 6). In allogeneic BMT re c i p i e n t s ,
G V H D - i n h i b i t o ry IL-12 treatment leads to an early burst of
I F N -g p roduction (by 1 day post-BMT) [1,18], much of
which is derived from natural killer (NK) cells of both donor
and host origin, and this burst is much less marked in IL-
1 2 – t reated recipients of syngeneic BMT [1] (B. Dey et al.,
unpublished observations). At later times (days 4 and 5),
s e rum IFN-g levels are markedly increased in GVHD con-
t rol mice, largely because of the activation of expanded host-
reactive donor T-helper cells [14,17]. This GVHD-associ-
ated IFN-g p roduction, along with host-reactive donor
T-helper cell expansion and activation, is markedly attenu-
ated in IL-12–protected mice, so that serum IFN-g l e v e l s
become markedly lower in this group than in GVHD con-
t rols [1]. Thus, the early burst of donor-derived IFN-g
appears to be responsible for the protective effect of IL-12
against GVHD. Consistent with a predominantly downmod-
u l a t o ry role for IFN-g in GVHD, even in the absence of IL-
12 administration, studies in the B6→B10.BR and the
A / J→B6 strain combinations have shown that GVHD mor-
tality occurs more rapidly when IFN-g– d e ficient donors are
used [31,17], and administration of exogenous IFN-g h a s
been shown to inhibit GVHD [32]. It will be of considerable
i n t e rest to compare the timing of IFN-g p roduction and the
cell types producing this cytokine in mice receiving X-irr a d i-
ation and those receiving g- i rradiation. Clearly, a better
understanding of these issues will be critical before IL-12 can
be considered for use as a means of separating GVHD and
GVL in the clinical setting. Since TBI used in conditioning
for clinical BMT may be delivered as g- i rradiation from a
6 0Co irradiator or as X-irradiation from a linear accelerator,
our observations of differing IL-12 toxicity with each tre a t-
ment are of considerable potential clinical relevance. Studies
in large animal preclinical models are clearly needed before
clinical assessment in this context can be justifie d .
Our studies also demonstrate that the timing of IL-12
administration in relation to the time of BMT is critical in
d e t e rmining its effect. Proximity to the time of BMT
appears to be critical in determining the degree of protec-
tion achieved, as better protection was observed when IL-12
was administered 1 hour before compared with 12 hours
after BMT. It is unlikely that the fall-off in the observ e d
protective effect of IL-12 administered 12 hours after BMT
is due to toxicity, since syngeneic BMT controls showed no
evidence of toxicity when IL-12 was administered at this
time. It is possible that high concentrations of IL-12 must
be present at the time of initial exposure of donor T cells to
recipient alloantigen for optimal inhibition of host-reactive
donor T-helper activation to occur. We have observed that
treatment with a protective dose of IL-12 is associated with
“ p re m a t u re” upregulation of the activation markers CD25
and CD69 and Fas on donor CD4 T cells, and that these
effects are apparent as early as 36 hours post-BMT. Further-
more, a role for Fas-mediated apoptosis of GVH-reactive T
cells has been suggested in the protective effect of IL-12,
since protection is less marked when Fas-deficient lpr
donors are used [30]. It is possible that these early changes
in donor T cell activation require the presence of high levels
of IFN-g, whose secretion is induced early by IL-12 treat-
ment [1] at the time of initial antigen exposure, and that a
delay in IL-12 administration after allogeneic BMT com-
promises these effects. Our observations are consistent with
those recently re p o rted in a model of autoimmune uveitis,
in which early, but not later, IL-12 administration also has
the paradoxical ability to inhibit a Th1-mediated disease via
an IFN-g–dependent mechanism [33]. 
The acceleration of mortality in recipients of allogeneic
BMT/spleen cell inocula when IL-12 was administered 36
hours post-BMT (Fig. 3A) may reflect a toxic effect of IL-
12, since syngeneic BMT recipients also showed some mor-
tality when IL-12 was administered at this time point. For
reasons not readily apparent, however, IL-12 administration
at 72 hours had a neutral effect, causing no obvious toxicity
in syngeneic BMT recipients and no acceleration of, or
delay in, GVHD-associated mortality. IL-12 administration
1 day before BMT had a marked toxic effect in both allo-
geneic and syngeneic BMT recipients. We postulate that
IL-12 administration at this time may induce recipient IFN-g
production, which is shown by the studies of IFN-g knock-
out mice to be capable of mediating toxic effects.
The ability of day 6 IL-12 administration to negate the
p rotective effect of IL-12 is of interest. Since GVHD in the
strain combination used in these studies is characterized by a
p o w e rful Th1-type response in this period, and IL-12 tre a t-
ment attenuates, but does not eliminate, this re s p o n s e
[30,1,17], it is possible that administration of IL-12 on day 6
may augment the reduced Th1 response that has developed in
I L - 1 2 – t reated mice and there f o re negate its protective eff e c t .
In summary, the results presented here indicate that the
timing of IL-12 administration and the mode of TBI deliv-
ery play a critical role in determining whether IL-12 medi-
ates a salutary or a deleterious effect in allogeneic BMT
recipients. Furt h e rm o re, whereas donor-derived IFN-g
mediates the protective effect of IL-12, the same cytokine,
except derived from the host, is re q u i red to induce IL-
12–induced toxicity when X-irradiation is used to deliver
TBI. The present study is the first, to our knowledge, to
demonstrate a critical role for IFN-g in this toxicity. These
results highlight the importance of evaluating IL-12 in
large-animal preclinical models before evaluating this novel
and potentially powerful means of separating GVHD from
GVL effects in the clinical setting.
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